for Temporary Mechanical
Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock.
Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of the heart and enabling patients to undergo necessary interventional procedures.
Patients with coronary artery disease (CAD) often require interventions such as angioplasty or stenting. Many patients with advanced disease or complicating comorbidities are not able to undergo percutaneous coronary interventional (PCI) procedures without the use of temporary support from a pVAD.
Patients that have a severe heart attack can suffer from cardiogenic shock (CS). During CS, a patient’s heart is too weak to adequately pump blood to vital organs and a pVAD may be required.
Next Generation Solution for Temporary Mechanical Circulatory Support
High-flow from a low-profile catheter pump designed to minimize vascular complications
Aiming to provide real-time, accurate monitoring of pump performance and location
Robust platform intended to address both high-risk PCI and cardiogenic shock patients
Supira Medical, Inc. is a portfolio company of Shifamed, LLC., a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.
Interested in joining the team?
View open positions with Supira Medical and Shifamed’s portfolio companies.
Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.
Company Appoints Seasoned Medtech Executive as President and CEO
CAMPBELL, Calif., March 5, 2020 – Supira Medical, formed by Shifamed as part of its medical innovation hub, announced today the closing of $35M in Series B financing. Officially closed on February 25, the financing was led by Cormorant Asset Management with participation from The Capital Partnership (TCP), 415 CAPITAL, AMED Ventures and Shifamed Angels. The funds will be used to advance product development and clinical efforts for the company’s next generation percutaneous ventricular assist device (pVAD). Additionally, the company announced the appointment of seasoned medical device executive, Dr. Nitin Salunke, as President and Chief Executive Officer.